AbbVie: Lymphoma trials

The registry lists 35 Lymphoma studies with AbbVie as lead sponsor. 0 are open to participants now and 16 have results posted.

Phase 1 22Phase 2 16Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory LymphomasCompletedNCT02401048Phase 1/2Results posted
• A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)CompletedNCT02264574Phase 3Results posted
• Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaCompletedNCT02142049Phase 1/2Results posted
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2Results posted
• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone LymphomaCompletedNCT01980628Phase 2Results posted
• A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p DeletionCompletedNCT01744691Phase 2Results posted
• Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01724346Phase 3Results posted
• Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLLCompletedNCT01722487Phase 3Results posted
• A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01578707Phase 3Results posted
• Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT01325701Phase 2Results posted
• Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01292135Phase 1Results posted
• Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01236391Phase 2Results posted
• Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLLCompletedNCT01217749Phase 1/2Results posted
• Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01109069Phase 2Results posted
• Study of the Safety and Tolerability of PCI-24781 in Patients With LymphomaCompletedNCT00724984Phase 1/2Results posted
• Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
• A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
• A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaCompletedNCT03181126Phase 1
• A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
• Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory LymphomaCompletedNCT02598570Phase 1
• Study Evaluating Venetoclax in Subjects With Hematological MalignanciesCompletedNCT02265731Phase 1/2
• A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's LymphomaWithdrawnNCT02095574Phase 1
• A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell LymphomaWithdrawnNCT02087878
• An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's LymphomaCompletedNCT01969695Phase 1
• A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01682616Phase 1
• A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01594229Phase 1
• IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01534715Phase 1
• A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaCompletedNCT01328626Phase 1
• A Safety and Tolerability Study of PCI-24781 in Subjects With CancerCompletedNCT01149668Phase 1
• Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell LymphomaCompletedNCT00849654Phase 1
• A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2
• Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00290004Phase 1/2
• Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00100711Phase 2
• Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's LymphomaCompletedNCT00086034Phase 2